Alzheimer's disease biomarker discovery using in silico literature mining and clinical validation

Journal of Translational Medicine

Simon Lovestone⁶  Julie Barnes³  Andrew Simmons⁶  Lars-Olof Wahlund⁸  Patrizia Mecocci⁴  Christian Spenger¹  Bruno Vellas⁷  Magda Tsolaki²  Iwona Kłoszewska⁹  Hilkka Soininen⁵  Jane Reed³  Joanna Riddoch-Contreras⁶  Nicola Day³  Ines Greco⁶ 

[1] Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden;3rd Department of Neurology, "G. Papanicolaou" Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece;BioWisdom Ltd, Cambridge, UK (now Instem Scientific;Institute of Gerontology and Geriatrics, University of Perugia, Perugia, Italy;University of Eastern Finland and University Hospital of Kuopio, Kuopio, Finland;King’s College London, Institute of Psychiatry, De Crespigny Park, London, SE5 8AF, UK;UMR INSERM 1027, Gerontopole, CHU Toulouse, University of Toulouse, Toulouse, France;Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden;Medical University of Lodz, Lodz, Poland

关键词: Literature mining;    in silico;    MRI;    Bioinformatics;    Intelligence network;    Urokinase-type plasminogen activator receptor (PLAUR);    Choline acetyltransferase (ChAt);    Biomarkers;    Proteomics;    Alzheimer’s disease;   

Others  :  829045
DOI  :  10.1186/1479-5876-10-217

 received in 2012-03-28, accepted in 2012-09-14,  发布年份 2012

【 摘 要 】

Background

Alzheimer’s Disease (AD) is the most widespread form of dementia in the elderly but despite progress made in recent years towards a mechanistic understanding, there is still an urgent need for disease modification therapy and for early diagnostic tests. Substantial international efforts are being made to discover and validate biomarkers for AD using candidate analytes and various data-driven 'omics' approaches. Cerebrospinal fluid is in many ways the tissue of choice for biomarkers of brain disease but is limited by patient and clinician acceptability, and increasing attention is being paid to the search for blood-based biomarkers. The aim of this study was to use a novel in silico approach to discover a set of candidate biomarkers for AD.

Methods

We used an in silico literature mining approach to identify potential biomarkers by creating a summarized set of assertional metadata derived from relevant legacy information. We then assessed the validity of this approach using direct assays of the identified biomarkers in plasma by immunodetection methods.

Results

Using this in silico approach, we identified 25 biomarker candidates, at least three of which have subsequently been reported to be altered in blood or CSF from AD patients. Two further candidate biomarkers, indicated from the in silico approach, were choline acetyltransferase and urokinase-type plasminogen activator receptor. Using immunodetection, we showed that, in a large sample set, these markers are either altered in disease or correlate with MRI markers of atrophy.

Conclusions

These data support as a proof of concept the use of data mining and in silico analyses to derive valid biomarker candidates for AD and, by extension, for other disorders.

【 授权许可】

   
2012 Greco et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Lovestone S, Guntert A, Hye A, Lynham S, Thambisetty M, Ward M: Proteomics of Alzheimer's disease: understanding mechanisms and seeking biomarkers. Expert Rev Proteomics 2007, 4(2):227-238.
• [2]Hampel H, Wilcock G, Andrieu S, Aisen P, Blennow K, Broich K, Carrillo M, Fox NC, Frisoni GB, Isaac M, et al.: Biomarkers for Alzheimer's disease therapeutic trials. Prog Neurobiol 2011, 95(4):579-593.
• [3]Blennow K, Hampel H, Weiner M, Zetterberg H: Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010, 6(3):131-144.
• [4]Verwey NA, Van Der Flier WM, Blennow K, Clark C, Sokolow S, De Deyn PP, Galasko D, Hampel H, Hartmann T, Kapaki E, et al.: A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. AnnClinBiochem 2009, 46(Pt 3):235-240.
• [5]Thambisetty M, Lovestone S: Blood-based biomarkers of Alzheimer's disease: challenging but feasible. BiomarkMed 2010, 4(1):65-79.
• [6]Thambisetty M, Tripaldi R, Riddoch-Contreras J, Hye A, An Y, Campbell J, Sojkova J, Kinsey A, Lynham S, Zhou Y, et al.: Proteome-based plasma markers of brain amyloid-beta deposition in non-demented older individuals. J Alzheimers Dis 2010, 22(4):1099-1109.
• [7]Thambisetty M, Simmons A, Velayudhan L, Hye A, Campbell J, Zhang Y, Wahlund LO, Westman E, Kinsey A, Guntert A, et al.: Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. ArchGenPsychiatry 2010, 67(7):739-748.
• [8]Klein J, Jupp S, Moulos P, Fernandez M, Buffin-Meyer B, Casemayou A, Chaaya R, Charonis A, Bascands JL, Stevens R, et al.: The KUPKB: a novel Web application to access multiomics data on kidney disease. FASEB J 2012, 26(5):2145-2153.
• [9]Reorganizing the protein space at the Universal Protein Resource (UniProt): Nucleic Acids Res. 2012, 40(Database issue):D71-75.
• [10]Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A: Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chem Res Toxicol 2010, 23(1):171-183.
• [11]Lovestone S, Francis P, Kloszewska I, Mecocci P, Simmons A, Soininen H, Spenger C, Tsolaki M, Vellas B, Wahlund LO, et al.: AddNeuroMed–the European collaboration for the discovery of novel biomarkers for Alzheimer's disease. AnnNYAcadSci 2009, 1180:36-46.
• [12]Simmons A, Westman E, Muehlboeck S, Mecocci P, Vellas B, Tsolaki M, Kloszewska I, Wahlund LO, Soininen H, Lovestone S, et al.: The AddNeuroMed framework for multi-centre MRI assessment of Alzheimer's disease: experience from the first 24 months. Int J Geriatr Psychiatry 2011, 26(1):75-82.
• [13]Simmons A, Westman E, Muehlboeck S, Mecocci P, Vellas B, Tsolaki M, Kloszewska I, Wahlund LO, Soininen H, Lovestone S, et al.: MRI measures of Alzheimer's disease and the AddNeuroMed study. AnnNYAcadSci 2009, 1180:47-55.
• [14]Westman E, Simmons A, Muehlboeck JS, Mecocci P, Vellas B, Tsolaki M, Kloszewska I, Soininen H, Weiner MW, Lovestone S, et al.: AddNeuroMed and ADNI: Similar patterns of Alzheimer's atrophy and automated MRI classification accuracy in Europe and North America. Neuroimage 2011, 58(3):818-828.
• [15]Westman E, Simmons A, Zhang Y, Muehlboeck JS, Tunnard C, Liu Y, Collins L, Evans A, Mecocci P, Vellas B, et al.: Multivariate analysis of MRI data for Alzheimer's disease, mild cognitive impairment and healthy controls. Neuroimage 2011, 54(2):1178-1187.
• [16]Velayudhan L, Killick R, Hye A, Kinsey A, Guentert A, Lynham S, Ward M, Leung R, Lourdusamy A, To AW, et al.: Plasma transthyretin as a candidate marker for Alzheimer's disease. J Alzheimers Dis 2012, 28(2):369-375.
• [17]Mancinella A, Mancinella M, Carpinteri G, Bellomo A, Fossati C, Gianturco V, Iori A, Ettorre E, Troisi G, Marigliano V: Is there a relationship between high C-reactive protein (CRP) levels and dementia? Arch Gerontol Geriatr 2009, 49(Suppl 1):185-194.
• [18]Kravitz BA, Corrada MM, Kawas CH: Elevated C-reactive protein levels are associated with prevalent dementia in the oldest-old. Alzheimers Dement 2009, 5(4):318-323.
• [19]Davis G, Baboolal N, Nayak S, McRae A: Sialic acid, homocysteine and CRP: potential markers for dementia. Neurosci Lett 2009, 465(3):282-284.
• [20]Schjeide BM, Schnack C, Lambert JC, Lill CM, Kirchheiner J, Tumani H, Otto M, Tanzi RE, Lehrach H, Amouyel P, et al.: The role of clusterin, complement receptor 1, and phosphatidylinositol binding clathrin assembly protein in Alzheimer disease risk and cerebrospinal fluid biomarker levels. Arch Gen Psychiatry 2011, 68(2):207-213.
• [21]Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, et al.: Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009, 41(10):1094-1099.
• [22]Parnetti L, Amici S, Lanari A, Romani C, Antognelli C, Andreasen N, Minthon L, Davidsson P, Pottel H, Blennow K, et al.: Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors. NeurolSci 2002, 23(Suppl 2):S95-S96.
• [23]Ewers M, Zhong Z, Burger K, Wallin A, Blennow K, Teipel SJ, Shen Y, Hampel H: Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease. Brain 2008, 131(Pt 5):1252-1258.
• [24]Kassner SS, Bonaterra GA, Kaiser E, Hildebrandt W, Metz J, Schroder J, Kinscherf R: Novel systemic markers for patients with Alzheimer disease? - a pilot study. Curr Alzheimer Res 2008, 5(4):358-366.
• [25]Blasi F, Sidenius N: The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett 2010, 584(9):1923-1930.
• [26]Smith HW, Marshall CJ: Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 2010, 11(1):23-36.
• [27]Blasi F, Carmeliet P: uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002, 3(12):932-943.
• [28]Davis J, Wagner MR, Zhang W, Xu F, Van Nostrand WE: Amyloid beta-protein stimulates the expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) in human cerebrovascular smooth muscle cells. J Biol Chem 2003, 278(21):19054-19061.
• [29]Walker DG, Lue LF, Beach TG: Increased expression of the urokinase plasminogen-activator receptor in amyloid beta peptide-treated human brain microglia and in AD brains. Brain Res 2002, 926(1–2):69-79.
• [30]Asahina M, Yoshiyama Y, Hattori T: Expression of matrix metalloproteinase-9 and urinary-type plasminogen activator in Alzheimer's disease brain. Clin Neuropathol 2001, 20(2):60-63.